12 results
To study whether dipyridamole reduces gastrointestinal absorption of metformin.
1. Creating a reproducible and valid method for adenosine measurement2. Studying the effect of dipyridamole on the endogenous adenosine concentration before and after CPT.
Primary objective: The primary objective of the study is to determine the effect of oral dipyridamole treatment on the innate immune response induced by a lipopolysaccharide (LPS) challenge. Various pro- and anti-inflammatory cytokines will be…
Explore 4 week post-treatment effect of seven day administration of dipyridamole on nucleoside transport inhibition.
The purpose of this project is to explore whether a short treatment with dipyridamole (2.5 days; i.e. 5 capsules) can reduce ischemia-reperfusion injury in the forearm.
The purpose of this study is to provide long-term safety data for Exelon® capsule and transdermal patch treatments, in particular the effect of Exelon® on worsening of the underlying motor symptoms of Parkinson*s Disease (PD), in patients with mild…
To test the hypothesis that dipyridamole improves tolerance to ischemia-reperfusion in patients undergoing elective PCI.
Creating a reproducible and valid method for adenosine measurement
The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.
To study the effect of oral pretreatment with dipyridamole on troponin-I release after CABG. Secondary objectives are whether oral pretreatment with dipyridamole reduces postoperative CABG arrhythmias, prolonged inotropic support, and duration of…
Primary objectiveTo investigate the efficacy of low dose colchicine (0.5mg/day) plus usual care (antiplatelet, lipid-lowering, antihypertensive treatment, and appropriate lifestyle advice) compared with usual care alone to prevent non-fatal…
Primary Objective: to obtain reliable estimates of the rates of vascular death and non-fatal stroke in patients with atrial fibrillation and a recent anticoagulation-associated ICH who are treated with apixaban versus those who are treated with APDs…